BFA
ARKG icon

Beaumont Financial Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Beaumont Financial Advisors’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6,041
Closed -$451K – 353
2021
Q3 		$451K Buy
6,041
+100
+2% +$8.39K 0.03% 217
2021
Q2 		$550K Buy
5,941
+237
+4% +$20.1K 0.04% 199
2021
Q1 		$506K Buy
5,704
+1,363
+31% +$135K 0.04% 192
2020
Q4 		$405K Buy
+4,341
New +$346K 0.04% 224

Other funds holding ARKG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Beaumont Financial Advisors's ARKG Position: Q4 2021 in Review

Beaumont Financial Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2021, closing a stake of 6,041 shares — an estimated $451K sold.

Beaumont Financial Advisors first reported a position in ARKG in Q4 2020 and held it in 4 quarters. The position peaked at $550K in Q2 2021. 460 funds tracked by Wall St. Rank hold ARKG as of Q4 2021.

  • Beaumont Financial Advisors reported no remaining ARK Genomic Revolution ETF position as of Q4 2021 after selling out during the quarter.
  • Beaumont Financial Advisors sold 6,041 ARK Genomic Revolution ETF shares in Q4 2021, an estimated $451K.
  • Beaumont Financial Advisors first reported a position in ARK Genomic Revolution ETF in Q4 2020 and held it in 4 quarters.
  • Beaumont Financial Advisors's ARK Genomic Revolution ETF position peaked at $550K in Q2 2021.
  • 460 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2021.

Based on Beaumont Financial Advisors's 13F filing for Q4 2021, filed 7 Feb 2022.